Abstract
Chimeric Antigen Receptor T-cell (CAR-T) therapy has transformed the treatment landscape for hematological malignancies, showing high efficacy in patients with relapsed or refractory (R/R) disease and otherwise poor prognosis in the pre-CAR-T era. These therapies have been usually administered in the inpatient setting due to the risk of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). However, there is a growing interest in the transition to outpatient administration due to multiple reasons. We review available evidence regarding safety and feasibility of outpatient administration of CD19 targeted and BCMA targeted CAR T-cell therapy with an emphasis on the implementation of outpatient CAR-T programs in community-based centers.
Publication Date
5-8-2024
Content Type
Article
PubMed ID:
Citation
Perez, A., Al Sagheer, T., Nahas, G. R., & Linhares, Y. P. L. (2024). Outpatient administration of CAR T-cell therapy: a focused review with recommendations for implementation in community based centers. Frontiers in immunology, 15, 1412002. https://doi.org/10.3389/fimmu.2024.1412002
Comments
This open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license. © 2024